Study results suggest that flotetuzumab demonstrates antileukemic activity in patients with primary induction failure and early-relapse acute myeloid leukemia.
Investigators compared ovarian reserve and assessed clinical characteristics in young women with sickle cell anemia vs those without the condition.
Response rates have improved as phase 1 studies shifted from chemotherapy to targeted agents for hematologic malignancies.
Even patients who did not achieve MRD negativity at 1 year had stable or decreasing disease levels.
Idecabtagene vicleucel showed clinical benefit and no toxicity concerns in patients with relapsed and/or refractory multiple myeloma.
Encouraging antitumor activity and durable responses were reported with odronextamab among patients with highly refractory B-cell NHLs.
Open-label, randomized clinical trial sought to determine noninferiority of subcutaneous and IV infusion cytarabine in young adults with AML.
Researchers identify factors that influence relapse after HSCT in patients with acute lymphoblastic leukemia.
Researchers sought to determine how and which factors contribute to healthcare utilization by patients with AML at the end of life.
Among patients with blood cancers, genetic variant profiles may negatively affect allo-HSCT outcomes including leukemia-free survival and acute GVHD.
